人前列腺良性增生和癌组织中雄激素受体转录水平
Androgen receptor transcript level in benign hypertrophy and carcinoma of the human prostate.
作者信息
Majumder P K, Wadhwa S N, Kumar V L
机构信息
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Urol Int. 1997;59(4):231-5. doi: 10.1159/000283069.
OBJECTIVE
Current reports suggest the presence of androgen receptor (AR) defects in prostate cancer. We have detected the AR mRNA in normal, benign hypertrophied (BPH) and carcinomatous (CaP) prostate tissues and evaluated the difference in the level of AR transcript in these groups.
MATERIALS AND METHODS
Cytoplasmic dot hybridization assay was used to measure the levels of AR mRNA in 21 normal, 45 BPH and 30 CaP specimens. Tissue samples of 14 CaP patients receiving endocrine treatment were also analyzed. Blots were autoradiographed and the intensity of the signal was measured by densitometry.
RESULTS AND CONCLUSIONS
The majority of cases in all the 3 groups were positive for the AR mRNA. All the patients who had received endocrine treatment were also positive for the AR mRNA. The level of the AR mRNA was significantly higher in BPH and treated CaP cases as compared to normal cases (p < 0.05). Among the CaP cases the level of AR transcript was significantly higher in the treated group as compared to the untreated group.
目的
当前报告提示前列腺癌中存在雄激素受体（AR）缺陷。我们检测了正常、良性增生（BPH）及癌性（CaP）前列腺组织中的AR mRNA，并评估了这些组中AR转录水平的差异。
材料与方法
采用细胞质斑点杂交法检测21例正常、45例BPH及30例CaP标本中AR mRNA的水平。还分析了14例接受内分泌治疗的CaP患者的组织样本。印迹进行放射自显影，并通过密度测定法测量信号强度。
结果与结论
所有3组中的大多数病例AR mRNA呈阳性。所有接受内分泌治疗的患者AR mRNA也呈阳性。与正常病例相比，BPH及接受治疗的CaP病例中AR mRNA水平显著更高（p < 0.05）。在CaP病例中，与未治疗组相比，治疗组中AR转录水平显著更高。
Zotero 插件